Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Recipient : PepTonic Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose-relationship of Vaginally Administrated Oxytocin in Postmenopausal Women
Details : Oxytocin is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atrophic Vaginitis.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 19, 2013
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Recipient : PepTonic Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Egetis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 14, 2012
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Egetis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
